Xtl Biopharmaceuticals annual stock-based compensation
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Xtl Biopharmaceuticals Stock-Based Compensation Growth & History (XTLB)
Xtl Biopharmaceuticals's stock-based compensation was $346,000 for fiscal 2025.
View full Xtl Biopharmaceuticals company overviewXtl Biopharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $346,000 | $82,000 | +31.06% |
| 2024 | 2024-12-31 | $264,000 | $261,000 | +8700.00% |
| 2023 | 2023-12-31 | $3,000 | −$11,000 | −78.57% |
| 2022 | 2022-12-31 | $14,000 | −$23,000 | −62.16% |
| 2021 | 2021-12-31 | $37,000 | −$14,000 | −27.45% |
| 2020 | 2020-12-31 | $51,000 | $46,000 | +920.00% |
| 2019 | 2019-12-31 | $5,000 | −$17,000 | −77.27% |
| 2018 | 2018-12-31 | $22,000 | −$15,000 | −40.54% |
| 2017 | 2017-12-31 | $37,000 | −$138,000 | −78.86% |
| 2016 | 2016-12-31 | $175,000 | $35,000 | +25.00% |
| 2015 | 2015-12-31 | $140,000 | — | — |
Xtl Biopharmaceuticals stock-based compensation trends
Over the last five fiscal years, Xtl Biopharmaceuticals's stock-based compensation increased from $51,000 to $346,000, a change of $295,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xtl Biopharmaceuticals source filings ↗